31 Mar, 2022
Up to now, Genor Biopharma has achieved the successful approval of GB242 (infliximab) was realized and the product will be commercialized with more NDA applications on the way. Successfully optimized its product pipeline and accelerated key clinical trials; established a global first-in-class/differentiated research and development platform for early identification of bi-specific/multi-specific antibodies in immune-oncology; started its journey of FIC/BIC R&D; and vigorously promoted global innovation and business development.
2032
30 Mar, 2022
The company has obtained the EC approval from the Bellberry HREC Ethics Committee in Australia, for the first-in-human (FIH) clinical trial of GB263T, a novel EGFR/cMET/cMET trispecific therapeutic antibody, in patients with advanced Non-Small Cell Lung Cancer (NSCLC) and other solid tumors.
2022
01 Mar, 2022
Genor Biopharma announced today that GB242 (infliximab) has received approval from China’s National Medical Products Administration (NMPA) for the treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriasis, Adult Ulcerative Colitis, Adult and Pediatric Crohn's Disease and Fistulising Crohn’s Disease.
2019
30 Dec, 2021
With the theme of "Gathering Momentum and Making a New Start", the “2021 New Economic Trends Lists” were officially released. Genor Biopharma was included on the "2021 New Economy Most Valuable Listed Company" list.
2005
28 Dec, 2021
Genor Biopharma today announced the appointment of several world-renowned experts in tumor immunology & clinical oncology to its Scientific Advisory Board (SAB).
2000